HC Wainwright reaffirmed their buy rating on shares of Viking Therapeutics Inc (NASDAQ:VKTX) in a report released on Sunday morning. They currently have a $6.00 price target on the stock.

Several other equities research analysts have also weighed in on VKTX. Maxim Group set a $5.00 target price on shares of Viking Therapeutics and gave the stock a buy rating in a report on Thursday, August 11th. Laidlaw lowered their target price on shares of Viking Therapeutics from $20.00 to $10.00 and set a buy rating on the stock in a report on Thursday, August 11th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $7.00.

Viking Therapeutics (NASDAQ:VKTX) opened at 1.28 on Friday. Viking Therapeutics has a 52 week low of $1.06 and a 52 week high of $7.14. The firm’s market cap is $24.67 million. The stock has a 50 day moving average of $1.34 and a 200 day moving average of $1.40.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, August 10th. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. Analysts anticipate that Viking Therapeutics will post ($0.98) EPS for the current year.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company has a portfolio of over five drug candidates under development. The Company’s lead clinical program, VK5211, is an orally available drug candidate for acute rehabilitation following non-elective hip fracture surgery.

5 Day Chart for NASDAQ:VKTX

Receive News & Ratings for Viking Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.